In summary, our study has demonstrated that ATO treatment induced differentiation of CSCs in HCC and potentiated the cytotoxic effects of 5‐FU/cisplatin through synergistic inhibition of the LIF/JAK1/STAT3 and NF‐kB signaling pathways. This evidence concerns the gene NFKB1 and hepatocellular carcinoma.